# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001628280-26-046936
Filing Date
2026-07-02
Accepted
2026-07-02 16:27:52
Documents
5
Period of Report
2026-07-01

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 6-K | telix-6kforprostactglobalp.htm | 6-K | 23016
2 | EX-99.1 | a20260702fdaalignmentpro.htm | EX-99.1 | 12445
3 | GRAPHIC | a20260702fdaalignmentpro001.jpg | GRAPHIC | 255121
4 | GRAPHIC | a20260702fdaalignmentpro002.jpg | GRAPHIC | 222045
5 | GRAPHIC | a20260702fdaalignmentpro003.jpg | GRAPHIC | 184572
| Complete submission text file | 0001628280-26-046936.txt |  | 948251

Mailing Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051
Business Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 61 3 9093 3855
Telix Pharmaceuticals Ltd (Filer) CIK: 0002007191 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-42128 | Film No.: 261151756
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)